Volume Alert - GILD 106.54 Gilead Sciences $GILD Hit a high

New Post Public Reply Private Reply Replies (0) Message Board

Nov 12, 2014 at 11:30 AM

Volume Alert - GILD 106.54 Gilead Sciences $GILD Hit a high today of 107.81 Closing the day 10:30 at 106.54 -1.47 -1.36% With a day low of 105.70 and a total volume of 3,398,247.

GILD Recent Posts: http://investorshangout.com/Gilead-Sciences-Inc-GILD-54232/

GILD Gilead Sciences Recent Headline News

Update: These 2 Combinations Will Further Strengthen Gilead's HCV Portfolio
IAEResearch - at Seeking Alpha - 12 mins ago

GILD: 106.85 (-1.16)

Early Glance: Biotechnology companies
AP - 24 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 106.85 (-1.16), AMGN: 161.31 (-1.11), CELG: 107.01 (-0.84)

Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - 2 hrs 41 mins ago
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 116.01 (-1.48), GILD: 106.85 (-1.16), ACHN: 13.16 (+0.68), DNDN: 0.16 (+0.01), AMGN: 161.31 (-1.11), ABBV: 63.84 (-0.01), REGN: 399.27 (+0.91)

Earnings Forecast Recap for Alibaba, Apple, Zynga, Gilead Sciences, Dendreon, and Juniper
PR Newswire - 2 hrs 44 mins ago
EarningForecast.com has issued six earnings forecast research reports with special focus on financial performance of the following stocks: Alibaba (NYSE:BABA), Apple (NASDAQ:AAPL), Zynga (NASDAQ:ZNGA), Gilead Sciences (NASDAQ:GILD), Dendreon (NASDAQ

NDN), and Juniper (NYSE:JNPR).
GILD: 106.85 (-1.16), DNDN: 0.16 (+0.01), ZNGA: 2.82 (+0.07), AAPL: 110.62 (+0.92), JNPR: 20.54 (+0.26), BABA: 117.35 (+2.81)

This Tiny Biotech Is Piggybacking on Gilead Sciences, Inc.'s Success
Todd Campbell, The Motley Fool - Motley Fool - 2 hrs 46 mins ago
Source: Gilead Sciences. Developing drugs that help established blockbusters work better is a major trend in biotechnology. It's a lower-stakes game because drug developers only need to show that their products can improve upon existing therapies,...
GILD: 106.85 (-1.16), ACHN: 13.16 (+0.68), MRK: 59.20 (-0.17)

Tracking The Parnassus Core Equity Fund
IVI Guy - at Seeking Alpha - Wed Nov 12, 6:45AM CST

WDFC: 77.10 (-0.56), SJR: 25.86 (-0.22), PRGO: 154.26 (-1.18), XYL: 37.33 (-0.02), CHRW: 72.10 (+0.35), MDLZ: 37.67 (-0.10), MKC: 72.79 (-0.43), MDU: 25.41 (-0.30), SYY: 38.81 (+0.29), PDCO: 44.63 (+0.36), PNR: 67.98 (-0.14), TRI: 38.10 (+0.18), UPS: 107.98 (-0.78), PEP: 96.91 (+0.21), AGN: 197.22 (+1.88), MSI: 63.64 (+0.09), NOV: 73.29 (+0.19), NWN: 46.87 (-0.62), EGN: 68.07 (-0.71), EBAY: 53.89 (-0.30), QCOM: 70.27 (+0.63), AMAT: 22.38 (-0.16), ACN: 83.74 (-0.20), AAPL: 110.62 (+0.92), MA: 84.14 (-0.45), SCHW: 28.73 (-0.12), STR: 23.78 (-0.51), SE: 39.03 (-0.30), GAS: 52.02 (-1.25), IRM: 37.99 (+0.16), WM: 49.35 (-0.01), CMP: 88.71 (+0.69), VRSK: 62.85 (-0.16), GILD: 106.85 (-1.16), EXPD: 44.03 (-0.23), TFX: 113.85 (-0.48), CVS: 89.19 (-0.57), PG: 89.63 (-0.04), PX: 126.08 (-0.62), NVS: 92.66 (-0.11)

Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 197.22 (+1.88), GILD: 106.85 (-1.16), ABBV: 63.84 (-0.01), BMY: 58.55 (-0.17)

Gilead up on Harvoni results
at Investor's Business Daily - Tue Nov 11, 5:30PM CST
The drugmaker said that its new Harvoni drug achieved cure rates of 96%-97% in a study of patients who had cirrhosis and had failed to respond to prior treatments. Harvoni is Gilead's (GILD) hepatitis C pill that combines its blockbuster Sovaldi drug...
GILD: 106.85 (-1.16)

Final Glance: Biotechnology companies
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 106.85 (-1.16), AMGN: 161.31 (-1.11), CELG: 107.02 (-0.83)

Achillion Jumps on Encouraging Data on its HCV Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 4:10PM CST
Shares of Achillion Pharmaceuticals (ACHN) soared over 27% after the company reported encouraging interim results on ACH-3102.
JNJ: 108.56 (-0.35), GILD: 106.85 (-1.16), ACHN: 13.16 (+0.68), AMAG: 34.74 (-0.14)

Merck down on hep C data
at Investor's Business Daily - Mon Nov 10, 6:00PM CST
Shares of big pharma Merck (MRK) fell hard after the latest data from its hepatitis C combination drug trial disappointed Wall Street. The drugmaker on Sun. reported interim data for its C-Swift trial, showing just 39% of patients were free of the...
GILD: 106.85 (-1.16), MRK: 59.20 (-0.17)

Gilead: Another Competitor Bites The Dust
Bret Jensen - at Seeking Alpha - Tue Nov 11, 1:10PM CST

GILD: 106.85 (-1.16)

Midday Glance: Biotechnology companies
AP - Tue Nov 11, 12:52PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 106.84 (-1.17), AMGN: 161.31 (-1.11), CELG: 107.02 (-0.83)

Conatus Pharmaceuticals (CNAT): Will Loss Narrow in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 12:50PM CST
Conatus Pharmaceuticals Inc, Inc. (CNAT) is expected to report third-quarter 2014 results on Nov 12.
MNK: 93.22 (-0.49), GILD: 106.86 (-1.15), CNAT: 6.87 (-0.19), ICPT: 155.82 (-17.31)

Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - Tue Nov 11, 10:13AM CST
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 106.86 (-1.15), ACHN: 13.16 (+0.68), MRK: 59.20 (-0.17), ABBV: 63.84 (-0.01), BMY: 58.55 (-0.17)

Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST

JNJ: 108.56 (-0.35), GILD: 106.86 (-1.15), ACHN: 13.16 (+0.68), CNAT: 6.87 (-0.19), MRK: 59.20 (-0.17), RGLS: 20.03 (-0.44), ABBV: 63.85 (unch), BMY: 58.55 (-0.17), ENTA: 43.16 (-0.06)

Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST

VRTX: 116.01 (-1.48), GILD: 106.86 (-1.15), MRK: 59.20 (-0.17), DNDN: 0.16 (+0.01), AZN: 74.13 (-0.07), TEVA: 58.20 (+0.01), ABBV: 63.85 (unch), GSK: 45.65 (-0.31), BMY: 58.55 (-0.17), NVS: 92.66 (-0.11)

Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 377.95 (-4.60), YHOO: 49.96 (+0.91), AMZN: 309.71 (-2.30), BIIB: 319.95 (-4.64), VRTX: 116.01 (-1.48), FEYE: 32.64 (-0.21), LNKD: 229.43 (-1.57), EBAY: 53.89 (-0.30), GILD: 106.86 (-1.15), AMGN: 161.31 (-1.11), ABBV: 63.85 (unch), REGN: 399.27 (+0.91), CELG: 107.02 (-0.83)

AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST

JNJ: 108.56 (-0.35), GILD: 106.86 (-1.15), ACHN: 13.16 (+0.68), CNAT: 6.87 (-0.19), MRK: 59.20 (-0.17), RGLS: 20.03 (-0.44), ABBV: 63.85 (unch), BMY: 58.55 (-0.17), ENTA: 43.16 (-0.06)

Gilead Sciences Inc. (GILD) Stock Research Links

GILD Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Unicoin’s 'RISE IN PINK' Blends Crypto and Charity

The New Face of Charitable Giving: Crypto and Cause Turning the spotlight on how blockchain and altruism can mesh, Unicoin's latest campaign isn’t just your average philanthropic endeavor. With 'RISE IN PINK', they're out to change the game, blending digital assets with a deep human cause—breast cancer awareness and support. Technology Meets Human Cause Imagine...

CardVault by Tom Brady Expands to Pittsburgh

Tom Brady’s CardVault Hits Pittsburgh’s Historic Strip District Pittsburgh just got another feather in its cap with CardVault by Tom Brady marking its 20th store at The Terminal. As if this city needed more sports excitement! Pittsburgh, with its die-hard Steelers, Penguins, and Pirates fans, snags a premium spot for sports collectibles. A Prime Spot for Serious...

Hidden Assets Guide: Essential Tool for Attorneys

Asset Searches: Why They Matter to Lawyers Some days you just have to get into the nitty-gritty of legal legwork, and today feels like one of those days. Asset Search USA has come out swinging with a practical guide that no attorney should ignore, especially if they're dealing with the shadowy world of hidden assets. What are we talking about here? We're talking about...

Qatar's Cultural Ventures Go Big Through 2030

Cultural Partners Lined Up Well Ahead In the swirling world of cultural diplomacy, Qatar's got its eyes set way beyond the skyline with their Years of Culture initiative. Announced recently, they've lined up partners through 2030, locking hands with Italy, the Netherlands, Switzerland, Portugal, and Spain in the coming years. Such moves aren't just for show—they’re...

Roadrunner's Bold Move: New LTL Service and Rate Hike

When you shake up the status quo in logistics, you better be ready for the ride. Roadrunner Freight is doing just that with the launch of its first-ever outbound Canada-to-U.S. LTL service. They're shaking up a market that's been bogged down with inefficiencies for far too long. This isn't just another lane to add to a map; it's a new passage for Canadian goods, paving a...

dMY IV Settlement: Investor Rights and Key Dates

dMY IV Settlement: What You Need to Know Listen up, folks! If you've got a stake in dMY Technology Group, Inc. IV, there's big news brewing. We're talking class action, settlement talks, and a cool $11 million on the line. Let's crack open what this means for you as a holder of dMY IV Class A common stock during December 2021's whirlwind. Who Can Get a Piece of the...

Podcast Giants Converge in Tennessee for POD U Summit

Nashville Becomes a Hotspot for Podcasters Amidst the strumming guitars and honky-tonk vibes of Nashville, Tennessee transformed into the epicenter of podcasting innovation thanks to Rebel Audio's inaugural summit, POD U. Here we had big names like Mike 'Big Mike' Majlak rubbing shoulders with sports experts and media moguls—a true concoction of voices shaping the...

Medicare Limits and Long-Term Care Planning Tips

Grappling with Medicare's Gaps Most folks hear Medicare and feel a sigh of relief—thinking it's a catch-all net for healthcare in your golden years. But hold on, when it comes to long-term care, Medicare's got more holes than Swiss cheese. Cindy Couyoumjian from Cinergy Financial lays it out pretty clear: Medicare doesn't cover what it calls 'custodial care'—you know,...

Gala Spotlights Veterans' Mental Health Support

Champions for Veterans Honored at Headstrong Gala If you ever wondered who stands in the trenches alongside veterans facing mental health battles, this year's Headstrong Gala offered a crystal-clear answer. Held on October 16 at Pier Sixty in New York City, this shiindig wasn’t just about schmoozing over canapés. It was about celebrating the grit and guts of those...

Blockchain Boom: Media Market to Hit $3.33B by 2035

Blockchain is Not Just for Bitcoin Anymore Who would've thought, right? Blockchain's no longer just the playground for cryptocurrency enthusiasts. Today, it's making waves in the media and entertainment sector. Latest numbers from Credence Research have this market set to explode from $748 million in 2025 to a jaw-dropping $3.33 billion by 2035. Yeah, folks, that's a...